Moon Won
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Korean J Gastroenterol. 2016 Feb;67(2):64-73. doi: 10.4166/kjg.2016.67.2.64.
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.
溃疡性结肠炎是一种结肠的慢性炎症性疾病，其特征为弥漫性黏膜炎症和便血性腹泻。主要治疗方法包括5-氨基水杨酸、类固醇、硫唑嘌呤以及抗肿瘤坏死因子α（TNF-α）抗体，如英夫利昔单抗、阿达木单抗和戈利木单抗。戈利木单抗是一种新型抗TNF-α药物，最近已被批准用于中重度溃疡性结肠炎患者。在临床前和临床研究中，其疗效和安全性已得到证实，与英夫利昔单抗和阿达木单抗相当。本综述将聚焦于戈利木单抗治疗溃疡性结肠炎。
